Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.52 |
| ▸ | CA2 | P00918 | 17/20 | 0.52 |
| ▸ | CA12 | O43570 | 15/20 | 0.52 |
| ▸ | CA9 | Q16790 | 15/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422276 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9KDR | |
| SCHEMBL5419122 | 0.92 | CA1 (0.58) | CA1CA2CA12CA9KDR | |
| SCHEMBL5183261 | 0.92 | CA1 (0.58) | CA1CA2CA12CA9KDR | |
| SCHEMBL5422279 | 0.87 | CA1 (0.53) | CA1CA2CA12CA9KDR | |
| SCHEMBL5434036 | 0.87 | CA1 (0.53) | CA1CA2CA12CA9KDR | |
| SCHEMBL5168743 | 0.87 | CA1 (0.54) | CA1CA2CA12CA9KDR | |
| SCHEMBL5427735 | 0.87 | CA1 (0.54) | CA1CA2CA12CA9KDR | |
| SCHEMBL5434032 | 0.87 | CA1 (0.53) | CA1CA2CA12CA9KDR | |
| SCHEMBL4907090 | 0.87 | MGAT2 (0.42) | CA1CA2CA12CA9KDR | |
| SCHEMBL4907092 | 0.87 | MGAT2 (0.42) | CA1CA2CA12CA9KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1009738-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | claimed |
| US-6541503-B2 | Preventing chemotherapy induced alopecia. | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | claimed |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | claimed |
| US-20070213403-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2007-09-13 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1009738-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6541503-B2 | Preventing chemotherapy induced alopecia. | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | disclosed |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | CA1 2095/4885CA2 2772/4885CA12 2681/4885 |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | CDK2, CDK1, CCNI | CA1 2237/4885CA2 2406/4885CA12 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.